Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure

Mayer-Sonnenfeld, Tehila; Har-Noy, Michael; Lillehei, Kevin O.; Graner, Michael W.

doi:10.3109/02656736.2013.796529

Cited by 7 publications

(11 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hyperthermia increases the expression of heat shock proteins and enhances antigen presentation by dendritic cells [84,85]. Via a range of effects, hyperthermia boosts the immune system to increase antitumour efficacy [86][87][88][89][90][91]. These effects may extend to tumour-bearing areas that are not effectively heated, via abscopal immune mediated effects [92].…”

Section: Discussionmentioning

confidence: 99%

Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer

Heijden

Dewhirst

2016

International Journal of Hyperthermia

View full text Add to dashboard Cite

Non-muscle-invasive bladder cancer is a challenging disease, even given its superficial nature. It is prone to multiple recurrences and progression to muscle-invasive cancer. These features of this disease contribute significantly to reduced quality of life as well as creating significant morbidity and even mortality. Randomised trials demonstrate that when hyperthermia is added to conventional mitomycin-C treatment that local control rates and progression-free survival are substantially improved. In this review we consider how hyperthermia can exert such beneficial effects. Some of the mechanisms presented are theoretical, while others are facts. It is hoped that this review will contribute rationale for further examination of mechanisms, because an understanding of such mechanisms may lead to even better chemotherapeutic approaches, as well as potential biomarkers for predicting and monitoring treatment success.ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer

Heijden

Dewhirst

2016

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…The nine papers in this special issue have been cited more than 380 times. The second special issue, on hyperthermia and tumour immunity, was published in 2013 and covered the role of HSPs in augmenting immunotherapy [24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41]. CumulaƟve citaƟons Figure 2.…”

Section: Heat Shock Proteinsmentioning

confidence: 99%

The future of biology in driving the field of hyperthermia

Dewhirst

Lee

Ashcraft

2016

International Journal of Hyperthermia

View full text Add to dashboard Cite

In 2011 Hanahan and Weinberg updated their well-established paper 'The hallmarks of cancer'. The rationale for that review and its predecessor was to produce a conceptual framework for future research in cancer. The original Hallmarks included: cell signalling to enhance tumour cell proliferation, acquisition of ability to evade growth suppressors, developing mechanisms to resist cell death, enabling replicative immortality, initiating angiogenesis and activating processes to enable invasion and metastasis. In the more recent paper, Hanahan and Weinberg added important new features to this composite paradigm. The new features were: (1) altered metabolism, (2) evasion of immune destruction, (3) tumour promoting inflammation, and (4) the cellular microenvironment. These four new features are the main focus of this review. Hanahan and Weinberg did not specifically include the physiological microenvironment which is dominated by hypoxia and acidosis. In this review we will consider these features in addition to the cellular and metabolic components of the microenvironment. The purpose of this review is to present a vision of emerging fields of study in hyperthermia biology over the next decade and beyond. As such, we are focusing our attention on pre-clinical studies, primarily using mice. The application of hyperthermia in human patients has been thoroughly reviewed elsewhere.

show abstract

“…Activated AlloStim ® express high density CD40L and type 1 cytokines, including IFN-ϒ, TNF-α and GM-CSF. AlloStim ® has been shown to modulate the immune systems of heavily pre-treated metastatic cancer patients (which resemble the senescent immune systems of the elderly) and has been used in protocols which were designed to elicit the same anti-tumor mechanism of allogeneic stem cell transplant procedures (graft vs tumor or "GVT") without the need for a matched donor, chemotherapy conditioning or risk of GVHD [30,31,[34][35][36][37][38].…”

Section: Immunity To Alloantigensmentioning

confidence: 99%

Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak

Har-Noy

2020

J Transl Med

Self Cite

View full text Add to dashboard Cite

Background: We present the rationale for a novel allo-priming approach to serve the elderly as a universal anti-virus vaccine, as well serving to remodel the aging immune system in order to reverse immunosenescence and inflammaging. This approach has the potential to protect the most vulnerable from disease and provide society an incalculable economic benefit. Allo-priming healthy elderly adults is proposed to provide universal protection from progression of any type of viral infection, including protection against progression of the current outbreak of COVID-19 infection, and any future variants of the causative SARS-CoV-2 virus or the next 'Disease X' . Allo-priming is an alternative approach for the COVID-19 pandemic that provides a back-up in case vaccination strategies to elicit neutralizing antibody protection fails or fails to protect the vulnerable elderly population. The allo-priming is performed using activated, intentionally mismatched, ex vivo differentiated and expanded living Th1-like cells (AlloStim ® ) derived from healthy donors currently in clinical use as an experimental cancer vaccine. Multiple intradermal injections of AlloStim ® creates a dominate titer of allo-specific Th1/CTL memory cells in circulation, replacing the dominance of exhausted memory cells of the aged immune system. Upon viral encounter, by-stander activation of the allo-specific memory cells causes an immediate release of IFN-ϒ, leading to development of an "anti-viral state", by-stander activation of innate cellular effector cells and activation of cross-reactive allo-specific CTL. In this manner, the non-specific activation of allospecific Th1/CTL initiates a cascade of spatial and temporal immune events which act to limit the early viral titer. The release of endogenous heat shock proteins (HSP) and DAMP from lysed viral-infected cells, in the context of IFN-ϒ, creates of conditions for in situ vaccination leading to viral-specific Th1/CTL immunity. These viral-specific Th1/CTL provide sterilizing immunity and memory for protection from disease recurrence, while increasing the pool of Th1/ CTL in circulation capable of responding to the next viral encounter. Conclusion:Allo-priming has potential to provide universal protection from viral disease and is a strategy to reverse immunosenescence and counter-regulate chronic inflammation (inflammaging). Allo-priming can be used as an adjuvant for anti-viral vaccines and as a counter-measure for unknown biological threats and bio-economic terrorism.

show abstract

Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure

Cited by 7 publications

References 47 publications

Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer

Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer

The future of biology in driving the field of hyperthermia

Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak

Contact Info

Product

Resources

About